Shanghai, China

Huimin Lu


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Huimin Lu: Innovator in Pharmaceutical Chemistry

Introduction

Huimin Lu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific kinases involved in various diseases. With a total of 2 patents, his work is paving the way for innovative treatments.

Latest Patents

One of Huimin Lu's latest patents is focused on a heterocyclic amide for inhibiting RIP1 kinase. This invention relates to a compound that is effective in treating diseases or disorders mediated by RIP1 kinase. The patent details the compound's formula, its pharmaceutically acceptable salts, and various isomers, including stereoisomers and enantiomers. The pharmaceutical composition derived from this compound holds promise for therapeutic applications.

Career Highlights

Huimin Lu is affiliated with the Chinese Academy of Sciences, where he conducts his research and development activities. His work is characterized by a strong emphasis on innovation and practical applications in medicine. His contributions have been recognized within the scientific community, and he continues to push the boundaries of pharmaceutical research.

Collaborations

Huimin Lu collaborates with notable colleagues, including Bing Zhou and Wei Tang. These partnerships enhance the research environment and foster the exchange of ideas, leading to groundbreaking advancements in their respective fields.

Conclusion

Huimin Lu's innovative work in pharmaceutical chemistry exemplifies the impact of targeted research on healthcare. His patents and collaborations reflect a commitment to developing effective treatments for complex diseases. The future looks promising as he continues to contribute to the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…